Europe - Frankfurt Stock Exchange - FRA:EWL - US28176E1082 - Common Stock
The current stock price of EWL.DE is 71.45 EUR. In the past month the price decreased by -2.72%. In the past year, price increased by 1.59%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 2M6.DE | MEDTRONIC PLC | 17.7 | 108.95B | ||
| SHL.DE | SIEMENS HEALTHINEERS AG | 18.67 | 50.32B | ||
| PHIA.AS | KONINKLIJKE PHILIPS NV | 15.26 | 21.74B | ||
| PHI1.DE | KONINKLIJKE PHILIPS NV | 15.32 | 21.84B | ||
| BIM.PA | BIOMERIEUX | 27.75 | 12.68B | ||
| OBCK.DE | OTTOBOCK SE & CO KGAA | 148.51 | 4.47B | ||
| AFX.DE | CARL ZEISS MEDITEC AG - BR | 23.51 | 3.60B | ||
| DIA.MI | DIASORIN SPA | 18.92 | 3.50B | ||
| DRW3.DE | DRAEGERWERK AG - PREF | 10.54 | 1.28B | ||
| DRW8.DE | DRAEGERWERK AG | 9.21 | 1.11B | ||
| ELN.MI | EL.EN. SPA | 21.23 | 1.09B | ||
| EUZ.DE | ECKERT & ZIEGLER SE | 23.2 | 957.88M |
Edwards Lifesciences Corp. engages in patient-focused medical innovations for heart disease and critical care monitoring. The company is headquartered in Irvine, California and currently employs 15,800 full-time employees. The company went IPO on 2000-03-27. The firm partners with clinicians and researchers and invests in research and development to improve care for those impacted by structural heart disease. Its product categories include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart. The company provides transcatheter heart valve replacement technologies designed for the minimally-invasive replacement of aortic heart valves. TAVR category includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra and the Edwards SAPIEN 3 Ultra RESILIA systems. TMTT category includes the PASCAL Precision transcatheter repair system, EVOQUE tricuspid valve replacement system and Cardioband tricuspid valve reconstruction system. Its INSPIRIS RESILIA aortic valve, offers RESILIA tissue and VFit technology. The company is managed in various geographical regions, such as United States, Europe, Japan and Rest of World.
EDWARDS LIFESCIENCES CORP
One Edwards Way
Irvine CALIFORNIA US
Employees: 15800
Phone: 19492502500
Edwards Lifesciences Corp. engages in patient-focused medical innovations for heart disease and critical care monitoring. The company is headquartered in Irvine, California and currently employs 15,800 full-time employees. The company went IPO on 2000-03-27. The firm partners with clinicians and researchers and invests in research and development to improve care for those impacted by structural heart disease. Its product categories include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart. The company provides transcatheter heart valve replacement technologies designed for the minimally-invasive replacement of aortic heart valves. TAVR category includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra and the Edwards SAPIEN 3 Ultra RESILIA systems. TMTT category includes the PASCAL Precision transcatheter repair system, EVOQUE tricuspid valve replacement system and Cardioband tricuspid valve reconstruction system. Its INSPIRIS RESILIA aortic valve, offers RESILIA tissue and VFit technology. The company is managed in various geographical regions, such as United States, Europe, Japan and Rest of World.
The current stock price of EWL.DE is 71.45 EUR. The price decreased by -1% in the last trading session.
EWL.DE does not pay a dividend.
EWL.DE has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
EDWARDS LIFESCIENCES CORP (EWL.DE) operates in the Health Care sector and the Health Care Equipment & Supplies industry.
EDWARDS LIFESCIENCES CORP (EWL.DE) has a market capitalization of 41.46B EUR. This makes EWL.DE a Large Cap stock.
You can find the ownership structure of EDWARDS LIFESCIENCES CORP (EWL.DE) on the Ownership tab.
ChartMill assigns a technical rating of 6 / 10 to EWL.DE. When comparing the yearly performance of all stocks, EWL.DE turns out to be only a medium performer in the overall market: it outperformed 60.72% of all stocks.
ChartMill assigns a fundamental rating of 7 / 10 to EWL.DE. EWL.DE gets an excellent profitability rating and is at the same time showing great financial health properties.
Over the last trailing twelve months EWL.DE reported a non-GAAP Earnings per Share(EPS) of 2.19. The EPS decreased by -3.75% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 23.25% | ||
| ROA | 10.31% | ||
| ROE | 13.4% | ||
| Debt/Equity | 0.06 |
42 analysts have analysed EWL.DE and the average price target is 81.68 EUR. This implies a price increase of 14.32% is expected in the next year compared to the current price of 71.45.
For the next year, analysts expect an EPS growth of 1.44% and a revenue growth 4.59% for EWL.DE